BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines cEO Summary Compensation Table Total (USD) ($)
DEF 14A Proxy Statement CEO Pay Ratio & Pay vs. Performance
Latest, FY2025
17,943,521
Period ended Dec 31, 2025
Change on a year earlier
-13.9%
20,836,439 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO Summary Compensation Table Total (USD) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17,943,521 | -13.9% | Proxy Statement (DEF 14A) (filed 2026-04-28) ↗ |
| FY2024 | Dec 31, 2024 | 20,836,439 | +10.1% | Proxy Statement (DEF 14A) (filed 2025-04-07) ↗ |
| FY2023 | Dec 31, 2023 | 18,925,730 | +4.9% | Proxy Statement (DEF 14A) (filed 2024-04-26) ↗ |
| FY2022 | Dec 31, 2022 | 18,047,667 | +7.8% | Proxy Statement (DEF 14A) (filed 2023-04-27) ↗ |
| FY2021 | Dec 31, 2021 | 16,748,546 | +16.2% | Proxy Statement (DEF 14A) (filed 2022-04-29) ↗ |
| FY2020 | Dec 31, 2020 | 14,409,330 | – | Proxy Statement (DEF 14A) (filed 2021-04-30) ↗ |
Cite this data
StockData. (2026). BeOne Medicines CEO Summary Compensation Table Total (USD) ($), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/ceo_sct
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.